AMENDMENT TO TERMINATION AGREEMENT

EXHIBIT 10.4

AMENDMENT TO TERMINATION AGREEMENT

     This Amendment to Termination Agreement (the “Amendment”) dated as of May 7, 2009 (the “Effective Date”) is an amendment to the Termination Agreement dated as of June 7, 2007 (the “Termination Agreement”), which in turn was a termination of the Development, Commercialization and Marketing Agreement (the “Agreement”) dated as of December 23, 2002 by and between Altus Pharmaceuticals Inc. (the successor in interest to Altus Biologics Inc.), a Delaware corporation, with its principal office at 610 Lincoln Street, Waltham, MA 02451 USA (“ALTUS”) and Dr. Falk Pharma GmbH, a German corporation, with its principal office at Leinenweberstrasse 5, 79041 Freiberg Germany (“FALK”).

BACKGROUND

     The Parties have agreed to alter the payments due from ALTUS to FALK under Section 1.2 of the Termination Agreement. This Amendment sets forth the terms and conditions applicable to such alteratio